Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

Shots:

• The P-III HAVEN (1,2,3, & 4) studies involve assessing of Hemlibra in patients with hemophilia A with/out factor VIII inhibitors resulted in zero treat bleeds @83wks., 87% with no treated joint bleeds, 92% with no spontaneous bleeds @25wks., improvement in QoL
• The P-IIIb STASEY study reinforces safety profile of Hemlibra in 88 patients with hemophilia A with factor VIII inhibitors aged ≥12 yrs. characterized in the HAVEN 1 clinical study resulted in no thrombotic microangiopathy with no new safety signals
• Hemlibra is a bispecific factor IXa & X directed Ab, activating the natural coagulation cascade and restoring the blood clotting process in patients with hemophilia A with/without factor VIII inhibitor and has received approval in 70+/40+ countries respectively

Click here to read full press release/ article | Ref: Roche | Image: New Dimension Exhibition Stands